Navigation Links
GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery
Date:3/26/2008

ST. JOSEPH, Mich., March 26 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today the release of MetaMiner Cystic Fibrosis, a first of its kind software and database platform designed to help advance drug discovery for cystic fibrosis, a life-threatening genetic disease. This novel, disease-specific tool will provide the cystic fibrosis research community with state-of-the art methods for integrating and analyzing cystic fibrosis data.

Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the Cystic Fibrosis Foundation, provided funding and guidance to the project with the goal of leveraging systems biology technology and accumulating data in order to accelerate drug discovery for this disease. Cystic fibrosis affects 30,000 people in the United States, and ten million Americans are symptomless carriers of a CF gene.

"MetaMiner Cystic Fibrosis is an important new tool for the cystic fibrosis research community," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "It will allow the integration of important new results with existing literature and speed up the rate of insights that can lead to new therapeutic interventions."

"We are very pleased to announce the completion of the initial phase of the project," said Julie Bryant, GeneGo's VP of Business Development. "We enjoyed working with the Foundation and the team of world-class experts they assembled for this project. In phase one, we built a database of all relevant small experiments information on the disease as well as over 30 cystic fibrosis specific pathway maps and networks. We believe this environment will help find a cure for cystic fibrosis faster as we move in to the next phase of the collaboration".

MetaMiner Cystic Fibrosis includes off-the-shelf GeneGo products -- MetaCore, MetaDrug and MapEditor -- as well as cystic fibrosis experiments content annotated by GeneGo in the form of disease maps, networks and a database of biomarkers and active compounds. A committee of researchers from the cystic fibrosis community guided the cystic fibrosis-specific annotation under the sponsorship of CFFT. MetaMiner Cystic Fibrosis provides researchers with the ability to interpret emerging data from global experiments, like arrays or proteomics, and link it with published literature on cystic fibrosis.

GeneGo's MetaMiner Cystic Fibrosis will enable cystic fibrosis researchers to visualize complex information and prioritize research initiatives. It will also help researchers to be open to other interpretations of their experimental data and allow them to rank the significance of their results. Additionally, MetaMiner Cystic Fibrosis will reduce the learning curve for researchers moving into the CF field and permit new investigators to understand outcomes more quickly.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.6(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.6(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
2. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
3. Elan Pharmaceuticals Joins GeneGos MetaTox Consortium
4. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
5. Psoriasis Cure Now Rolls Out First National Short Sleeve Day Saturday
6. Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S.
7. BET Rolls Out a Weekend of Award-Winning, HIV-Themed Programming Commemorating World AIDS Day
8. Tasker Products Rolls Out Scalder Application at Two New Poultry Processors Facilities
9. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
10. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
11. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: